Tumor-based gene expression biomarkers to predict survival following curative intent resection for stage I lung adenocarcinoma.

ABSTRACT:

Background

Prognostic biomarkers are needed in clinical setting to predict outcome after resection for early-stage lung adenocarcinoma. The goal of this study is to validate tumor-based single-gene expression biomarkers with demonstrated prognostic value in order to move them along the clinical translation pipeline.

Methods

Prognostic genes were selected from the literature and the best candidates measured by quantitative real-time polymerase chain reaction (qPCR) in tumors of 233 patients with stage I adenocarcinoma. Significant prognostic genes were then validated in an independent set of 210 patients matching the first set in terms of histology, stage, and clinical data.

Results

Eleven genes with demonstrated prognostic value were selected from the literature. Comp

SUBMITTER: Clemenceau A 

PROVIDER: S-EPMC6245750 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature